The invention relates to a Myc dominant negative mutant called Omomyc for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and in particular for treatment of cancer.